Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03552471 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT03552471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03552471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
July 12, 2018
Completion date
December 19, 2022
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 gene mutation, brca2 gene mutation, folate receptor alpha positive, platinum resistant ovarian cancer, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent uterine carcinosarcoma, recurrent uterine corpus carcinoma, recurrent uterine serous carcinoma